Skip to main content

Table 1 Patient characteristics

From: Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

 

Clinical benefit (n = 4)

No clinical benefit (n = 8)

Median age (range)

57 (38-78)

67 (52-77)

Sex

1 female

3 female

3 male

5 male

M-stage

0 M1A

2 M1A

2 M1B

0 M1B

2 M1C

6 M1C

Median baseline LDH

156

211 (183-438)

Karnofsky Performance

90 (90-100)

90 (90-100)